JAZZ Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: May 07, 2026

Report Source: 2026 1st Quarter Report

Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals PLC. Stock Analysis JAZZ

United States Health Care Large Cap Report:
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. The company is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. The company has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Read More

Jazz Pharmaceuticals PLC (JAZZ) Chart

Key Statistics of Jazz Pharmaceuticals PLC (JAZZ)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$225.00$230.82

Today's Open

$229.07

Volume

1.35M

P/E Ratio (TTM)

-

52 Week Range

$97.50$235.00

Market Cap

13.32B

Avg. Volume

990.79K

Dividend Yield

-

Financial Metrics & Statements of Jazz Pharmaceuticals PLC (JAZZ)

FAQ's for Jazz Pharmaceuticals PLC (JAZZ)

  • According to Musaffa’s Shariah screening methodology, Jazz Pharmaceuticals PLC (JAZZ) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Disclaimer

The content provided on this website is intended solely for informational and educational purposes. Musaffa is a technology, data, education, and research company. We are not licensed financial service provider by the authorized relevant financial service regulator in India or any other regulatory government body, and we do not offer or facilitate any trading, brokerage, investment, or financial advisory services. We do not deliberately target an audience seeking financial services.

By accessing this website, you acknowledge and confirm that you are seeking information relating to Musaffa of your own accord, and that there has been no form of solicitation, advertisement, or inducement by Musaffa or its members. Musaffa shall not be liable for the consequences of any action taken by relying on the material or information provided on this website. The contents of this website are the intellectual property of Musaffa.